Our top pick for
Building a portfolio
Kura Oncology, Inc is a biotechnology business based in the US. Kura Oncology shares (KURA) are listed on the NASDAQ and all prices are listed in US Dollars. Kura Oncology employs 88 staff and has a market cap (total outstanding shares value) of USD0.00.
|52-week range||USD$9.8875 - USD$43|
|50-day moving average||USD$28.5097|
|200-day moving average||USD$33.0625|
|Wall St. target price||USD$41.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.568|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-12.92%|
|Return on equity TTM||-21.61%|
|Market capitalisation||USD$1.9 billion|
TTM: trailing 12 months
There are currently 9.2 million Kura Oncology shares held short by investors – that's known as Kura Oncology's "short interest". This figure is 0.5% up from 9.1 million last month.
There are a few different ways that this level of interest in shorting Kura Oncology shares can be evaluated.
Kura Oncology's "short interest ratio" (SIR) is the quantity of Kura Oncology shares currently shorted divided by the average quantity of Kura Oncology shares traded daily (recently around 811943.47826087). Kura Oncology's SIR currently stands at 11.27. In other words for every 100,000 Kura Oncology shares traded daily on the market, roughly 11270 shares are currently held short.
However Kura Oncology's short interest can also be evaluated against the total number of Kura Oncology shares, or, against the total number of tradable Kura Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kura Oncology's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Kura Oncology shares in existence, roughly 140 shares are currently held short) or 0.1604% of the tradable shares (for every 100,000 tradable Kura Oncology shares, roughly 160 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kura Oncology.
Find out more about how you can short Kura Oncology stock.
We're not expecting Kura Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Kura Oncology's shares have ranged in value from as little as $9.8875 up to $43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kura Oncology's is 1.9868. This would suggest that Kura Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. .
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.